期刊文献+

rCBV变化与VEGF表达对胶质母细胞瘤术后放疗病人生存期的预测研究 被引量:1

Predictive study of rCBV change and VEGF expression for survival time of glioblastoma patients treated by postoperative radiotherapy
在线阅读 下载PDF
导出
摘要 目的探讨相对脑血容量(relative cerebral blood volume,rCBV)变化和血管内皮生长因子(vascular endothelialgrowth factor,VEGF)表达对胶质母细胞瘤全切手术后辅助放射治疗病人的无进展生存期(PFS)和总生存期(OS)的预测作用。方法回顾性分析16例外科全切术后辅助放射治疗的胶质母细胞瘤病人的临床资料。在放射治疗前和放射治疗中(累计放射剂量为30 Gy)各进行1次灌注成像检查,计算rCBV值。免疫组化检测VEGF表达。采用Kaplan-Meier生存曲线分析PFS和OS。结果不同年龄、VEGF表达和rCBV变化的病人,其在PFS的差异具有统计学意义(均P<0.05)。仅有VEGF表达不同的病人在OS的差异具有统计学意义(P<0.05)。结论 VEGF表达和rCBV变化可以作为判定胶质母细胞瘤PFS的预测物。同时,VEGF表达可以作为判定胶质母细胞瘤OS的预测物。 Objective To analyze the predictive effects of change of relative cerebral blood volume(rCBV) and expression of vascular endothelial growth factor(VEGF) on progression free survival(PFS) and overall survival(OS) in glioblastoma patients treated by total resection assisted with postoperative radiotherapy.Methods Clinical data of 16 glioblastoma patients treated by total resection assisted with postoperative radiotherapy were analyzed retrospectively.The dynamic susceptibility contrast-enhanced perfusion MR imaging was performed to calculate the rCBV before and during radiotherapy(the total radiation dose,30 Gy).The expression of VEGF was detected by immunohistochemistry.PFS and OS were analyzed by Kaplan-Meier survival curves.Results There were significant differences in PFS between patients with different ages,VEGF expressions and rCBV changes(all P 0.05).There was obvious difference in OS between patients with different expressions of VEGF(P 0.05).Conclusions VEGF expression and rCBV changes can be considered as the predictors of PFS,and VEGF expression can also be a predictor of OS in glioblastoma patients.
出处 《中国微侵袭神经外科杂志》 CAS 2012年第4期160-163,共4页 Chinese Journal of Minimally Invasive Neurosurgery
基金 国家重点基础研究发展计划(编号:2011CB 707804) 河南省科技厅国际合作项目(编号:114300510016)
关键词 胶质母细胞瘤 脑血容量 相对 血管内皮生长因子 放射治疗 灌注成像 glioblastoma cerebral blood volume relative vascular endothelial growth factor radiotherapy perfusion weighted imaging
作者简介 通讯作者:江涛.Email:jiangta0369@sohu.com
  • 相关文献

参考文献1

  • 1Zlobec I,Steele R,Compton CC. VEGF as a predictive marker of rectal tumor response to preoperative radiotherapy[J].Cancer,2005,(11):2517-2521.

同被引文献15

  • 1Reardon DA, Galanis E, DeGroot JF, et ol. Clinical trial end points for high-grade glioma: the evolving landscape [J]. Neuro Oncol, 2011, 13(3): 353-361.
  • 2Chinot OL, Macdonald DR, Abrey LE, et ol. Response assessment criteria for glioblastoma: practical adaptatior and implementation in clinical trials of antiangiogenic therapy [J]. Curr Neurol Neurosci Rep, 2013, 13(5): 347.
  • 3Wen PY, Norden AD, Drappatz J, et al. Response assess.ment challenges in clinical trials of gliomas [J]. Curr Oncol Rep, 2010, 12(1): 68-75.
  • 4Lutz K, Radbruch A, Wiestler B, et al. Neuroradiological response criteria for high-grade gliomas [J]. Clin Neuro- mdiol, 2011, 21(4): 199-205.
  • 5Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group [J]. J Clin Oncol, 2010, 28(11): 1963-1972.
  • 6Vogelbaum MA, Jost S, Aghi MK, et al. Application of novel response/progression measures for surgically deliver- ed therapies for gliomas: Response Assessment in Neuro- Oncology (RANO) Working Group [J]. Neurosurgery, 2012, 70(1): 234-244.
  • 7Clarke JL, Chang SM. Neuroimaging: diagnosis and response assessment in glioblastoma [J]. Cancer J, 2012, 18(1): 26- 31.
  • 8Kruser TJ, Mehta MP, Robins HI. Pseudoprogression after glioma therapy: a comprehensive review [J]. Expert Rev Neurother, 2013, 13(4): 389-403.
  • 9Pouleau HB, Sadeghi N, Baleriaux D, et ol. High levels of cellular proliferation predict pseudoprogression in glioblas- toma patients [J]. Int J Oncol, 2012, 40(4): 923-928.
  • 10Van Mieghem E, Wozniak A, Geussens Y, et o1. Defining pseudoprogression in glioblastoma multiforme [J]. Eur J Neurol, 2013, 20(10): 1335-1341.

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部